Cambridge, MA – May 2, 20223 -- hC Bioscience (Private) announced that Leslie Williams, president and CEO, will deliver a presentation on the science behind tRNA-based therapies and the company's therapeutic programs at the Locust Walk RNA Innovation Conference on Tuesday, May 9, 2023, at 11:00 a.m. ET.
The Locust Walk RNA Innovation Conference is hosted in partnership with Dr. Frank Slack, Director of the Beth Israel RNA Medicine Initiative, and Dr. Phil Zamore, Director of the UMass Chan RNA Medicine Institute. Locust Walk is hosting a virtual one-day investor and partner conference exploring innovations in RNA research and development, including:
- Protein Expression
- RNA Editing
- RNA-Mediated Protein & Transcriptome Regulation
- RNA Targeting SMOLs
- Translation Inhibition
- Novel Delivery Approaches
The event will showcase cutting-edge science, industry trends, and high-value opportunities in next-generation in RNA R&D. The format will include keynote speakers, company presentations, and panel discussions featuring leaders and luminaries from industry, academia, and the investment community.
hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics to target protein dysfunction. hC Bioscience’s innovative approach to precision protein editing has the potential to treat genetically defined conditions, which account for 10-15% of all human disease. The lead platform in development is directed at restoring protein function in diseases caused by nonsense mutations or premature termination codons (PTCs). A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.
To learn more, visit hCBioscience.com
